ORIGINALE Published: Insulin Glargine Neutral on CVD, CancerORIGINALE Published: Insulin Glargine Neutral on CVD, Cancer
The results of the follow-on trial to ORIGIN have been published and reassure that insulin glargine has neutral effects on cardiovascular outcomes and cancer in patients with dysglycemia or diabetes. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Diabetes | Endocrinology | Heart | Insulin | Lantus